NSC 663284（SPS8I1;DA3003-1）|cas 383907-43-5|DC Chemicals

Cas No.:	383907-43-5
Chemical Name:	NSC 663284
Synonyms:	NSC 663284;5,8-Quinolinedione, 6-chloro-7-[[2-(4-morpholinyl)ethyl]amino]-;6-Chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione;6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione;NSC 663284 (DA3003-1,Cdc25 Phosphatase Inhibitor II);6-Chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione;6-Chloro-7-[[2-(4-Morpholinyl)ethyl]aMino]-5,8-quinolinedione;DA3003-1;DA-3003-1;G13464;6-Chloro-7-((2-morpholinoethyl)amino)quinoline-5,8-dione;NCGC00092289-01;CDC25 Phosphatase Inhibitor II, NSC 663284;7-N-(Aminoethyl-4-morpholino)-6-chloro-5,8-quinolinedione;6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione;SMR002530674;CS-7519;383907-43-5;6-chloro-7-[2-(4-morpholinyl)ethylamino]quinoline-5,8-dione;SPS8I1;HMS3676L16;NCGC00092289-02;EX-A8020;NSC 663284, >=98% (HPLC), solid;6-Chloro-7-[[2-(4-morpholinyl)ethyl]amino]-5,8-quinolinedione;6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}-5,8-dihydroquinoline-5,8-dione;NSC 663284?;NSC-663284;DS-017054;BCP16027;HMS3268K22;NSC663284;SCHEMBL2556224;MS-24764;HY-100034;SDCCGSBI-0654266.P001;Q27163848;MFCD08276924;HMS3412L16;DTXSID50327512;AKOS024456823;CY8W2F69MW;BRD-K03109492-001-02-2;DA 3003-1;DA 3003-01;DA-3003-01;BDBM420306;CHEBI:92053;5,8-QUINOLINEDIONE, 6-CHLORO-7-((2-(4-MORPHOLINYL)ETHYL)AMINO)-;5,6-chloro-7-[[2-(4-morpholinyl)ethyl]amino]-;MLS006010693;NCI60_021732;BRD-K03109492-001-01-4;UNII-CY8W2F69MW
SMILES:	O=C(C(Cl)=C1NCCN2CCOCC2)C3=C(N=CC=C3)C1=O
Formula:	C₁₅H₁₆N₃O₃Cl
M.Wt:	321.75884
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	NSC 663284 is a Cdc25 dual specificity phosphatases inhibitor with an IC50 of 0.21 μM.
Target:	IC50: 0.21 μM (Cdc25 dual specificity phosphatase)[1]
In Vivo:	NSC 663284 inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. After a single i.v. dose of 5 mg/kg, NSC 663284 is not detectable in plasma or tissues beyond 5 min. Following NSC 663284 treatment of tumor-bearing SCID mice, reduces glutathione concentrations in HT29 tumor are decreased to a greater extent and remained decreased for longer than the reduced glutathione concentrations in liver and kidneys[2].
In Vitro:	The Cdc25 dual specificity phosphatases have central roles in coordinating cellular signaling processes and cell proliferation. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B2, and Cdc25C with Ki values of 29, 95, and 89 nM, respectively. NSC 663284 blocks cellular Erk dephosphorylation caused by ectopic Cdc25A expression. NSC 663284 displays a strong preference for Cdc25B2 as compared with VHR or PTP1B, the relative IC50 values for Cdc25B2 are 20- and 450-fold lower than for VHR or PTP1B, respectively. NSC 663284 blocks cell proliferation and the actions of cellular cdc25a. NSC 663284 has a mean IC50 value in the NCI 60 Cell Human Tumor Panel of 1.5 (0.6 µM when cells are treated for 48 h). Most sensitive are human breast cancer MDA-MB-435 and MDA-N cells, which have IC50 values of 0.2 µM[1].
Animal Administration:	Mice: C.B.-17 SCID mice bearing HT29 human colon carcinoma xenografts are stratified into the following groups of 9-10 animals: Control, vehicle control, positive control (gemcitabine, 50 mg/kg/dose i.v.), NSC 663284 at the following doses: 2, 3 or 5 mg/kg/dose i.v.. The mice are dosed every 4 days for 6 doses, and body weights and tumor volumes are recorded twice weekly. Tumors are measured with calipers, and tumor volumes are calculated. Mice are followed for 3 weeks following the completion of the dosing to monitor tumor regrowth. In a second study, C.B.-17 SCID mice bearing MDA-MB-435 human breast cancer xenografts are stratified to the same treatment groups, except that paclitaxel at 20 mg/kg i.v. every 7 days is used as the positive control[2].
References:	[1]. Lazo JS, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001 Nov 22;44(24):4042-9. [2]. Guo J, et al. Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). Anticancer Res. 2007 Sep-Oct;27(5A):3067-73.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77714	S3226	S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models.
DC77387	AUR1545	AUR1545 is a selective degrader of KAT2A and KAT2B. AUR1545 can be used in the cancer research, including studies on AML (Acute myeloid leukemia), SCLC (Small-cell carcinoma), and NEPC (Neuroendocrine Prostate Cancer).
DC77822	JNJ-77242113 (Icotrokinr)	Icotrokinra (JNJ-77242113, JNJ-2113, PN-235) is an orally available and selective antagonist of the IL-23 receptor. It also inhibits IL-23–induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM and suppresses IL-23–induced IFN-γ production in NK cells with an IC50 of 18.4 pM. It also exhibits anti-inflammatory activity in a TNBS-induced colitis model in rats and holds potential for studying psoriasis, psoriatic arthritis, and inflammatory bowel disease.
DC77088	T025	T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.